MX2007008017A - Polipeptidos que se ligan a br3 y usos de los mismos. - Google Patents

Polipeptidos que se ligan a br3 y usos de los mismos.

Info

Publication number
MX2007008017A
MX2007008017A MX2007008017A MX2007008017A MX2007008017A MX 2007008017 A MX2007008017 A MX 2007008017A MX 2007008017 A MX2007008017 A MX 2007008017A MX 2007008017 A MX2007008017 A MX 2007008017A MX 2007008017 A MX2007008017 A MX 2007008017A
Authority
MX
Mexico
Prior art keywords
polypeptides
methods
bind
relates
present
Prior art date
Application number
MX2007008017A
Other languages
English (en)
Inventor
Henry B Lowman
Gerald R Nakamura
Germaine Fuh
Mark S Dennis
Christine M Ambrose
Mercedesz Balazs
Laura Deforge
Stephen D Hurst
Chingwei V Lee
Flavius Martin
Dhaya Seshasayee
Melissa Starovasnik
Jeffrey S Thompson
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2007008017A publication Critical patent/MX2007008017A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Abstract

La presente invencion se refiere a anticuerpos y polipeptidos novedosos de ligadura a BR3, incluyendo polipeptidos antagonistas y agonistas. La presente invencion tambien se refiere al uso de los anticuerpos y polipeptidos de ligadura a BR3 en, v.gr., metodos de tratamiento, metodos de seleccion, metodos de diagnostico, ensayos y metodos de purificacion de proteinas.
MX2007008017A 2004-12-31 2005-12-23 Polipeptidos que se ligan a br3 y usos de los mismos. MX2007008017A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64032304P 2004-12-31 2004-12-31
PCT/US2005/047072 WO2006073941A2 (en) 2004-12-31 2005-12-23 Polypeptides that bind br3 and uses thereof

Publications (1)

Publication Number Publication Date
MX2007008017A true MX2007008017A (es) 2007-09-12

Family

ID=36588679

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007008017A MX2007008017A (es) 2004-12-31 2005-12-23 Polipeptidos que se ligan a br3 y usos de los mismos.

Country Status (14)

Country Link
US (2) US20080181888A1 (es)
EP (1) EP1838735A2 (es)
JP (1) JP2008526205A (es)
KR (1) KR20070107687A (es)
CN (1) CN101120021A (es)
AP (1) AP2007004034A0 (es)
AU (1) AU2005323025A1 (es)
BR (1) BRPI0518994A2 (es)
CA (1) CA2595112A1 (es)
EA (1) EA200701211A1 (es)
IL (1) IL183353A0 (es)
MX (1) MX2007008017A (es)
NO (1) NO20072721L (es)
WO (1) WO2006073941A2 (es)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
US20110129414A1 (en) * 2005-11-15 2011-06-02 Balyasnikova Irina V Single Chain Fragment of Monoclonal Antibody 9B9 and Uses Thereof
RS54111B1 (en) * 2005-11-18 2015-12-31 Glenmark Pharmaceuticals S.A. ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
AU2006318539B2 (en) 2005-11-23 2012-09-13 Genentech, Inc. Methods and compositions related to B cell assays
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
WO2008008482A2 (en) * 2006-07-13 2008-01-17 Genentech, Inc. Altered br3-binding polypeptides
GB0620729D0 (en) * 2006-10-18 2006-11-29 Ucb Sa Biological products
WO2008098145A1 (en) * 2007-02-07 2008-08-14 University Of Washington Methods for modulating antigen-specific b cell responses
CA2676766A1 (en) * 2007-02-09 2008-08-21 Genentech, Inc. Anti-robo4 antibodies and uses therefor
NZ583367A (en) * 2007-07-16 2012-10-26 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
CN101802013B (zh) 2007-07-16 2014-07-02 健泰科生物技术公司 人源化抗cd79b抗体和免疫偶联物及使用方法
WO2009092068A1 (en) 2008-01-18 2009-07-23 President And Fellows Of Harvard College Methods of detecting signatures of disease or conditions in bodily fluids
MX2010008437A (es) 2008-01-31 2010-11-25 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
SI2315780T1 (sl) 2008-07-17 2015-11-30 Novartis Ag Sestavki in postopki uporabe za terapevtska protitelesa
KR102100066B1 (ko) 2008-10-14 2020-04-10 제넨테크, 인크. 이뮤노글로불린 변이체 및 그의 용도
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
BRPI0917592B1 (pt) 2008-12-09 2021-08-17 Genentech, Inc Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
BRPI0918204A2 (pt) 2008-12-23 2015-12-08 Genentech Inc igv variante composição farmaceutica e kit
TW201544123A (zh) 2009-03-20 2015-12-01 Genentech Inc 抗-ｈｅｒ抗體
MX2012002909A (es) 2009-09-17 2012-04-19 Hoffmann La Roche Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
PE20120998A1 (es) 2009-09-30 2012-08-14 Genentech Inc Metodos para el tratamiento del cancer usando antagonistas de notch
EP2509626B1 (en) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c antibodies and methods using same
WO2011088111A1 (en) * 2010-01-12 2011-07-21 Genentech, Inc. ANTI-PlGF ANTIBODIES AND METHODS USING SAME
NZ724971A (en) 2010-02-24 2019-06-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
TWI667346B (zh) 2010-03-30 2019-08-01 中外製藥股份有限公司 促進抗原消失之具有經修飾的FcRn親和力之抗體
CN101851278B (zh) * 2010-05-26 2013-03-13 石药集团中奇制药技术（石家庄）有限公司 B细胞激活因子拮抗剂及其制备方法与用途
AU2011280936A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting prenatal or pregnancy-related diseases or conditions
AU2011280997A1 (en) 2010-07-23 2013-02-28 President And Fellows Of Harvard College Methods of detecting autoimmune or immune-related diseases or conditions
SG10201505723UA (en) 2010-07-23 2015-09-29 Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
US20130266940A1 (en) 2010-07-23 2013-10-10 President And Fellows Of Harvard College Methods of Detecting Kidney-Associated Diseases or Conditions
WO2012012725A2 (en) 2010-07-23 2012-01-26 President And Fellows Of Harvard College Methods of detecting diseases or conditions using phagocytic cells
US9963504B2 (en) 2010-09-02 2018-05-08 Vaccinex, Inc. Anti-CXCL13 antibodies and methods of using the same
US9458240B2 (en) * 2010-12-10 2016-10-04 Novartis Pharma Ag Anti-BAFFR antibody formulations
AU2012206431B2 (en) 2011-01-14 2015-04-30 UCB Biopharma SRL Antibody molecules which bind IL-17A and IL-17F
MX340640B (es) 2011-04-01 2016-07-19 Immunogen Inc Metodos para aumentar la eficacia de la terapia contra el cancer con receptor 1 de folato (folr1).
KR101648960B1 (ko) * 2011-04-15 2016-08-22 서울대학교산학협력단 접합 물질과 코티닌과의 접합체에 항-코티닌 항체가 결합된 복합체 및 이의 용도
EP3939996A1 (en) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
AU2012319150B2 (en) 2011-10-05 2017-08-17 Genentech, Inc. Methods of treating liver conditions using Notch2 antagonists
US9890213B2 (en) 2012-03-02 2018-02-13 Vaccinex, Inc. Methods for the treatment of B cell-mediated inflammatory diseases
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
RU2014136886A (ru) 2012-03-27 2016-05-20 Дженентек, Инк. Диагностика и виды лечения, связанные с ингибиторами her3
US9216219B2 (en) 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
KR20240005129A (ko) 2012-08-31 2024-01-11 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
EP2920300B1 (en) * 2012-11-13 2018-09-12 F.Hoffmann-La Roche Ag Enrichment of antigen-specific plasmablasts
WO2014121053A1 (en) 2013-01-31 2014-08-07 Vaccinex, Inc. Methods for increasing immunoglobulin a levels
EP3385717A3 (en) 2013-03-09 2018-10-24 Harry Stylli Methods of detecting prostate cancer
EP4202441A3 (en) 2013-03-09 2023-07-26 Immunis.AI, Inc. Gene expression profile in macrophages for the diagnosis of cancer
CA2903480A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
US20160053023A1 (en) 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
EP3019240B1 (en) 2013-07-09 2024-03-13 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
IL293871A (en) 2013-08-30 2022-08-01 Immunogen Inc Antibodies and assays for the detection of folate receptor 1
US10435474B2 (en) 2013-12-24 2019-10-08 Ossianix, Inc. Baff selective binding compounds and related methods
US20170240631A1 (en) 2014-08-08 2017-08-24 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2016040843A1 (en) 2014-09-11 2016-03-17 Harry Stylli Methods of detecting prostate cancer
LT3262071T (lt) 2014-09-23 2020-06-25 F. Hoffmann-La Roche Ag Anti-cd79b imunokonjugatų naudojimo būdai
SG11201703667SA (en) 2014-11-05 2017-06-29 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
DK3280441T3 (da) 2015-04-07 2021-11-15 Alector Llc Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
BR112017023378A2 (pt) * 2015-05-01 2018-07-24 Inhibrx Lp moléculas de direcionamento do sistema de secreção do tipo iii
SG10201912085WA (en) 2015-06-12 2020-02-27 Alector Llc Anti-cd33 antibodies and methods of use thereof
US11174313B2 (en) 2015-06-12 2021-11-16 Alector Llc Anti-CD33 antibodies and methods of use thereof
JP6807606B2 (ja) 2015-07-16 2021-01-06 インヒブルクス インコーポレイテッド 多価及び多重特異性ｄｒ５結合融合タンパク質
KR20180054639A (ko) 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
JP6880006B2 (ja) 2015-09-17 2021-06-02 イミュノジェン， インコーポレイテッド 抗ｆｏｌｒ１免疫複合体を含む治療組み合わせ
CN117069841A (zh) 2015-10-06 2023-11-17 艾利妥 抗trem2抗体及其使用方法
EP3368575A2 (en) 2015-10-29 2018-09-05 Alector LLC Anti-siglec-9 antibodies and methods of use thereof
US11472877B2 (en) 2016-03-04 2022-10-18 Alector Llc Anti-TREM1 antibodies and methods of use thereof
CN109641957B (zh) * 2016-06-06 2022-10-04 希望之城 Baff-r抗体及其用途
JP7070932B2 (ja) * 2016-06-06 2022-05-18 シティ・オブ・ホープ Ｂａｆｆ－ｒ標的化キメラ抗原受容体修飾ｔ細胞及びその使用
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
EP3589658A1 (en) 2017-08-03 2020-01-08 Alector LLC Anti-cd33 antibodies and methods of use thereof
MD3601358T2 (ro) 2017-08-03 2023-10-31 Alector Llc Anticorpi anti-TREM2 și metode de utilizare a acestora
EP3456737B1 (en) 2017-09-19 2024-02-14 Tillotts Pharma Ag Antibody variants
SI3456736T1 (sl) 2017-09-19 2021-06-30 Tillotts Pharma Ag Variante protitelesa
EP3456738A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Antibody variants
EP3456739A1 (en) 2017-09-19 2019-03-20 Tillotts Pharma Ag Use of anti-tnfalpha antibodies for treating wounds
EP4219540A3 (en) 2017-10-10 2023-12-06 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
EP3625263A4 (en) 2017-10-27 2021-05-05 New York University ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
UA128113C2 (uk) 2018-05-25 2024-04-10 ЕЛЕКТОР ЕлЕлСі Анти-sirpa антитіла і способи їхнього застосування
WO2019236965A1 (en) 2018-06-08 2019-12-12 Alector Llc Anti-siglec-7 antibodies and methods of use thereof
LT3618928T (lt) 2018-07-13 2023-04-11 Alector Llc Anti-sortilino antikūnai ir jų panaudojimo būdai
US20200140533A1 (en) 2018-11-02 2020-05-07 Annexon, Inc. Compositions and methods for treating brain injury
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
WO2020154889A1 (zh) * 2019-01-29 2020-08-06 上海鑫湾生物科技有限公司 具有Fc突变体的抗体与效应细胞的组合、用途和制法
CN114026126A (zh) * 2019-05-01 2022-02-08 纽约大学 抗半乳糖凝集素-9抗体及其用途
KR20220110537A (ko) 2019-12-05 2022-08-08 알렉터 엘엘씨 항-trem2 항체 사용 방법
EP4073119A1 (en) 2019-12-12 2022-10-19 Alector LLC Methods of use of anti-cd33 antibodies
US20230159637A1 (en) 2020-02-24 2023-05-25 Alector Llc Methods of use of anti-trem2 antibodies
CA3169967A1 (en) 2020-03-24 2021-09-30 Genentech, Inc. Tie2-binding agents and methods of use
MX2022012182A (es) 2020-04-03 2022-12-08 Alector Llc Metodos de uso de anticuerpos anti-trem2.
IL297980A (en) * 2020-05-08 2023-01-01 Alpine Immune Sciences Inc Immunomodulatory proteins that inhibit april and baff and methods of using them
CN112999346A (zh) * 2021-03-04 2021-06-22 华中科技大学同济医学院附属协和医院 Baff抗体在制备治疗炎症性肠病药物中的应用
WO2023081898A1 (en) 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2364997A3 (en) * 1999-01-15 2012-07-04 Genentech, Inc. Polypeptide variants with altered effector function
UA83458C2 (uk) * 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
JP2005510208A (ja) * 2001-08-03 2005-04-21 ジェネンテック・インコーポレーテッド ＴＡＣＩｓ及びＢＲ３ポリペプチドとその用途
WO2003074679A2 (en) * 2002-03-01 2003-09-12 Xencor Antibody optimization

Also Published As

Publication number Publication date
WO2006073941A2 (en) 2006-07-13
AU2005323025A1 (en) 2006-07-13
CA2595112A1 (en) 2006-07-13
BRPI0518994A2 (pt) 2008-12-02
AP2007004034A0 (en) 2007-06-30
JP2008526205A (ja) 2008-07-24
US20080181888A1 (en) 2008-07-31
NO20072721L (no) 2007-10-01
CN101120021A (zh) 2008-02-06
IL183353A0 (en) 2008-04-13
WO2006073941A9 (en) 2007-07-05
WO2006073941A3 (en) 2006-08-31
KR20070107687A (ko) 2007-11-07
US20100280227A1 (en) 2010-11-04
EP1838735A2 (en) 2007-10-03
EA200701211A1 (ru) 2007-12-28

Similar Documents

Publication Publication Date Title
MX2007008017A (es) Polipeptidos que se ligan a br3 y usos de los mismos.
JOP20190017A1 (ar) أجسام مضادة ترتبط مع مستقبل cgrp بشري
EA200801621A1 (ru) Антитела, направленные на her-3, и их применение
MX2009013824A (es) Proteinas de enlace de antigeno que enlazan par-2.
MY163480A (en) Sclerostin binding agents
MX348432B (es) Epitopes.
UA96139C2 (uk) Антитіло до нейропіліну-1 (nrp1)
WO2006118772A3 (en) Fcrn antibodies and uses thereof
HK1074670A1 (en) Sets of digital antibodies directed against short epitopes, and methods using same
MX2008009886A (es) Anticuerpos que enlazan par-2.
WO2006088700A3 (en) Human ring specific bnp antibodies
HK1102012A1 (en) Antibodies and molecules derived therefrom that bind to steap-1 proteins
TW200626614A (en) Human monoclonal antibodies to influenza M2 protein and methods of making and using same
WO2008008482A3 (en) Altered br3-binding polypeptides
TW200745159A (en) IL-6 binding proteins
EP3300739A3 (en) Antibodies and related molecules that bind to 161p2f10b proteins
MX2010004615A (es) Anticuerpos monoclonales contra proteina c. activada e inactivada.
WO2005028497A3 (en) Receptor binding peptides derived from the sars s protein
EP2631248A3 (en) Treatment of tumors using specific anti-L1 antibody
MXPA05011085A (es) Composiciones y metodos relacionados a stop-1.
WO2007144619A3 (en) Antibodies selectively binding aggregated prion protein 106-126 and uses thereof
TW200718711A (en) Polypeptides that bind BR3 and uses thereof
WO2005094159A3 (en) Methods of identifying neoplasm-specific antibodies and uses thereof
TW200619226A (en) Identification and characterization of function-blocking anti-Ed-B-fibronectin antibodies
WO2006008266A3 (en) Factor xi-binding proteins

Legal Events

Date Code Title Description
FA Abandonment or withdrawal